EKSO Ekso Bionics Holdings Inc

Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton pioneer, announced today that Glenn Davis and Thomas Looby have joined the company to amplify its sales and marketing strategies. Davis brings over 20 years of sales experience with Siemens Healthcare and a comprehensive understanding of how to drive revenue within the Healthcare Sector in major and emerging markets while Looby adds his experience in systematically driving adoption of novel, high tech solutions to critical healthcare problems, most recently with Given Imaging. Both Davis and Looby have considerable experience in medical device market development and will work in tandem to build a robust business for Ekso Bionics.

Glenn Davis joined Ekso Bionics after spending over 23 years with Siemens Healthcare where most recently as Vice President-Worldwide Marketing-Ultrasound Division he established a team of sales and marketing professionals that continually challenged the status quo. In 2013 he led the launch of the world's first wireless ultrasound, the Acuson Freestyle ultrasound system, into the marketplace to critical acclaim. "Glenn's extensive medical device industry experience makes him a key addition to Ekso Bionics," said Frank Moreman, chief operating officer. "The significant increase in attention from neuro-rehabilitation clinics necessitated an addition to our team who could jump in and help deploy our disruptive medical technology to centers worldwide. We are very pleased that we were able to find someone of Glenn's caliber to fulfill this role."

Glenn Davis added, "Ekso represents the next significant breakthrough in medical technology; I want to be able to say to my five daughters that I was a part of an innovation that fundamentally changed people's lives."

Thomas Looby has spent the last 20 years building recognizable and trusted brands at world class companies including Bayer and Eastman Kodak, and most recently at Given Imaging as Chief Marketing Officer, where he was responsible for worldwide market development for PillCam capsule endoscopy and other novel solutions to gastrointestinal diseases. "We are very fortunate to find Tom," said Chief Executive Officer Nathan Harding. "With his critical experience in medtech and robotics and his deep understanding of emerging market opportunities, Tom is well suited to lead the development and execution of Ekso's global hospital and rehabilitation marketing strategy."

"Ekso is about more than just leading edge technology, it is about empowering humans to do more than they can imagine," said Thomas Looby. "That is the real measuring stick of a company; to be able to inspire customers who use your products but also to touch the hearts of those who don't."

Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics' lead product, EksoTM, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.

About Ekso Bionics Holdings, Inc. (OTCQB:EKSO)

Since 2005, Ekso Bionics (http://www.eksobionics.com) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Facebook: www.facebook.com/eksobionics Twitter: @eksobionics YouTube: http://www.youtube.com/user/EksoBionics/

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's Current Report on Form 8-K filed on January 23, 2014. The Company does not undertake to update these forward-looking statements.

CONTACT: Media Contact:
         Heidi Darling, Marketing Manager
         Phone: 415.302.4777
         hdarling@eksobionics.com
         
         Investor Contact:
         Lauren Glaser, Vice President
         Phone: 646.378.2972
         lglaser@troutgroup.com